INS and Insulin resistance: Thiazolidinediones (TZDs), pioglitazone and rosiglitazone, are potent and selective receptor agonist of peroxisome proliferator–activated receptor-γ (PPAR-γ) nuclear receptors that improve insulin sensitivity in muscle, adipose and hepatic tissue; reducing systemic insulin resistance.